Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Says Q3 Revenue Jumps 43 Percent as Loss Narrows; Firm Ups '06 Guidance

NEW YORK (GenomeWeb News) — Sequenom today said third-quarter revenues increased 43 percent as R&D spending rose 16 percent and losses decreased by 16 percent.
 
Total receipts for the three months ended Sept. 30 increased to $6.5 million from $4.6 million year over year.
 
R&D spending increased to $3 million from $2.6 million year over year.
 
The company said losses declined to $5.3 million from $6.3 million in the year-ago period.
 
Sequenom said it had around $29.6 million in cash, cash equivalents, short-term investments, and restricted cash as of Sept. 30.
 
The company said it is increasing its 2006 financial guidance to $27 million from $24 million, which would be a 39-percent improvement over 2005.
 
Despite the positive results, shares in Sequenom were down 6.5 perecent, or $.23, at $3.30 in mid-afternoon trading today.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.